GlassScriptPhysician profile
David M Keller
NPI 1578026969
$3,432.15
in general payments reported to CMS, 2019-2025
35 companies · $858 in 2025
The $858 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.43 · 2022: $706 · 2023: $925 · 2024: $929 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,711.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $670.01 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Seapearl East, INC | $378.48 | 2022-2023 | |
| Lilly USA, LLC | $244.33 | 2022-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $211.54 | 2022-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $206.80 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $170.10 | 2022-2025 | |
| Exact Sciences Corporation | $165.33 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $135.36 | 2022-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $114.72 | 2024-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $111.32 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $99.65 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $97.86 | 2022-2023 | Eliquis, Camzyos |
| Pfizer INC. | $96.39 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $84.21 | 2024-2025 | Ingrezza |
| Stryker Corporation | $75.84 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.77 | 2023-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $45.00 | 2024 | Voquezna |
| Lundbeck LLC | $43.73 | 2024 | Rexulti |
| Hologic Sales and Service, LLC | $43.26 | 2023-2025 | Aptima |
| Seqirus USA INC | $37.60 | 2025 | Flucelvax, Fluad |
| Abbvie INC. | $37.43 | 2022-2023 | |
| Corium, LLC | $35.68 | 2022 | |
| Cranial Technologies, INC | $27.88 | 2024 | Doc Band |
| Merck Sharp & Dohme LLC | $25.81 | 2024 | Vaxelis, Gardasil 9, Gardasil |
| Vanda Pharmaceuticals INC. | $25.76 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.70 | 2023 | |
| Alexion Pharmaceuticals, INC. | $22.52 | 2023 | Ultomiris |
| Organon LLC | $21.74 | 2025 | Nuvaring, Nexplanon |
| Paratek Pharmaceuticals, INC. | $20.99 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.19 | 2025 | Keveyis |
| Kowa Pharmaceuticals America, INC. | $18.29 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.00 | 2022 | |
| Bardy Diagnostics, INC. | $14.98 | 2022 | |
| Tonix Medicines, INC. | $14.45 | 2025 | Tonmya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.